author-photo

Edward James Olhava

Millennium Pharmaceuticals

24

Papers

2329

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Targeting the NLRP3 inflammasome in inflammatory diseases

2018 Nature Reviews Drug Discovery
Show All
- Source
- Cite
- Save
Citations (517)
Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases

2018 Nature Reviews Drug Discovery
Show All
- Source
- Cite
- Save
Citations (104)
Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia

2017 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (30)
Modulateurs de nlrp3

2017
Show All
- Source
- Cite
- Save
Citations (0)
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human

2016 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (16)
Abstract 2701: Characterization of acquired EPZ-5676 resistance in cell line models of MLL rearranged leukemia

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Sels, co-cristaux, formes amorphes, et formes cristallines d'un inhibiteur d'arginine méthyltransférase

2015
Show All
- Source
- Cite
- Save
Citations (0)
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.

2014 Biopharmaceutics & Drug Disposition
Show All
- Source
- Cite
- Save
Citations (57)
DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells

2014 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (79)
Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

2014 Blood
Show All
- Source
- Cite
- Save
Citations (4)